Investor

Overview Share information Financial calendar Reports & presentations Governance

Investor relations

We are committed to providing all shareholders and potential investors with consistent, transparent, and relevant financial information. This section offers key insights into Lifecare.

NOK –

Last updated 1970-01-01 00:00:00

Change +0.00

Volume 0,000

High 0.00 NOK

Low 0.00 NOK

Ongoing Right Issue

Lifecare ASA has launched a partially underwritten rights issue of new shares. The EEA prospectus was approved by the Financial Supervisory Authority of Norway on 6 January 2026.

The subscription period runs from 7 January 2026 at 09:00 (CET) to 21 January 2026 at 16:30 (CET).

The prospectus and subscription form for the rights issue are available at

www.dnb.no/emisjoner and www.sb1markets.no/transaksjoner/ .

Company presentation

Lifecare is a Norwegian med-tech company developing sensors to measure and monitor biomarkers. We focus on diabetes, aiming to bring the next generation of continuous glucose monitoring (GCM) systems to improve diabetes management for humans and pets.

Investment case

Diabetes is a trillion-dollar global healthcare challenge. CGMs is the fastest growing diabetes tech segment, representing a USD 30 billion market opportunity. Within CGMs, implantable solutions represent a USD 5 billion potential market. Read more about how Lifecare intends to capture a share of the implantable CGM market and create value for our stakeholders here.

Stock exchange notices

IR contacts

Joacim Holter

Chief Executive Officer

+47 400 59 040 joacim.holter@lifecare.no

Renete Kaarvik

Chief Financial Officer

+47 94838242 renete.kaarvik@lifecare.no